The MUSTT study: evaluating testing and treatment

Area of Science:

• Cardiology
• Electrophysiology
• Clinical Trials

Background:

• Nonsustained ventricular tachycardia (NSVT) and poor left ventricular function (LV-EF ≤ 40%) in coronary artery disease (CAD) patients identify high risk for sudden cardiac death (SCD).
• Electrophysiologically guided therapy aims to prevent adverse outcomes in these patients.

Purpose of the Study:

• To evaluate the efficacy of electrophysiologically guided antiarrhythmic drug (AAD) therapy versus no therapy in high-risk CAD patients with NSVT.
• To assess the role of inducibility testing in risk stratification for sudden arrhythmic death or cardiac arrest (SCD/CA).

Main Methods:

• The Multicenter Unsustained Tachycardia Trial (MUSTT) enrolled high-risk CAD patients with LV-EF ≤ 40% and NSVT.
• Patients underwent electrophysiological (EP) testing to assess inducibility of sustained ventricular tachycardia.
• Participants were randomized to EP-guided AAD therapy or no therapy, with a primary endpoint of SCD/CA.

Main Results:

• EP-guided AAD therapy showed a trend towards reduced SCD/CA compared to no treatment (18% vs. 32% at 60 months).
• Subgroup analysis revealed that the benefit of AADs was primarily associated with concurrent implantable cardioverter-defibrillator (ICD) implantation.
• Patients who were not inducible for sustained ventricular tachycardia had significantly better outcomes regardless of treatment, highlighting inducibility as a key risk stratifier.

Conclusions:

• Electrophysiological testing is a crucial tool for risk stratification in high-risk CAD patients.
• Stand-alone antiarrhythmic drug therapy guided by EP testing has limited value in preventing SCD/CA.
• Implantable cardioverter-defibrillators (ICDs) are essential for significantly reducing SCD/CA in this patient population, as demonstrated by MUSTT findings supporting MADIT study data.